ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation



Summary

ULBP2 CAR-T cells show promise in improving gastric cancer immunotherapy by targeting and killing tumor cells and simultaneously disrupting the tumor microenvironment. The key mechanism involves inhibiting the activation of cancer-associated fibroblasts (CAFs), which are crucial in promoting tumor growth and suppressing the immune system. By targeting cells expressing ULBP2, including tumor cells and activated CAFs, the CAR-T cells not only directly kill cancer cells but also indirectly weaken the protective shield created by CAFs. This dual action allows for better immune cell infiltration and a more effective anti-tumor response in gastric cancer.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!